Abstract: A tool for drilling a borehole through a formation. The tool comprises a body, blades having rotationally leading surfaces extending from the tool body, cutting elements secured at least partially within cutting element pockets, and linear or rounded transition surfaces between the cutting element pockets and the rotationally leading surface of the blades. The rounded transition surfaces have a radius of curvature between about 3 and 150 millimeters.

Abstract: Systems and methods for artificial intelligence enabled instant diagnostic follow-up can provide efficiency to the medical diagnosis process by providing multiple examinations in the same medical visit for medical workflows that previously required multiple visits. The systems and methods can provide further medical benefit by implementing triaging systems to ensure the most urgent cases are seen immediately.

Abstract: A tool for drilling a borehole through a formation. The tool comprises a body, blades having rotationally leading surfaces extending from the tool body, cutting elements secured at least partially within cutting element pockets, and linear or rounded transition surfaces between the cutting element pockets and the rotationally leading surface of the blades. The rounded transition surfaces have a radius of curvature between about 3 and 150 millimeters.

Abstract: A method of performing debris clean-up following a disaster event can include creating an electronic load ticket for a pre-registered debris transporter to transport a load of debris from a site of debris origin to a site where the load of debris is to be emptied from the transporter; following transport of the load of debris to the second site, reading, from the electronic information storage device and to a portable computing device, the information uniquely identifying the debris transporter and the electronic load ticket; and upon verification that no alteration has been made to the transporter, receiving at the portable computing device information describing the load of debris that has been transported. In some implementations, the electronic load ticket includes information identifying the geographic location of debris origin, and is electronically stored on a portable electronic information storage device that contains information uniquely identifying the debris transporter.

Abstract: A method of performing debris clean-up following a disaster event can include creating an electronic load ticket for a pre-registered debris transporter to transport a load of debris from a site of debris origin to a site where the load of debris is to be emptied from the transporter; following transport of the load of debris to the second site, reading, from the electronic information storage device and to a portable computing device, the information uniquely identifying the debris transporter and the electronic load ticket; and upon verification that no alteration has been made to the transporter, receiving at the portable computing device information describing the load of debris that has been transported. In some implementations, the electronic load ticket includes information identifying the geographic location of debris origin, and is electronically stored on a portable electronic information storage device that contains information uniquely identifying the debris transporter.

Abstract: A compound of Formula (I), or pharmaceutically acceptable salts and/or hydrates or prodrugs thereof, wherein Formula (I) has the structure: is provided, wherein R1-R7 are defined herein. These compounds are useful in medicaments for treating a disease selected from the group consisting of Alzheimer's disease, amyloid angiopathy, cerebral amyloid angiopathy, systemic amyloidosis, hereditary cerebral hemorrhage with amyloidosis of the Dutch type, inclusion body myositis, mild cognitive impairment (MCI) and Down's syndrome, in a subject.

Abstract: A compound of Formula (I), or pharmaceutically acceptable salts and/or hydrates or prodrugs thereof, wherein Formula (I) has the structure: is provided, wherein R1-R7 are defined herein. These compounds are useful in medicaments for treating a disease selected from the group consisting of Alzheimer's Disease, amyloid angiopathy, cerebral amyloid angiopathy, systemic amyloidosis, hereditary cerebral hemorrhage with amyloidosis of the Dutch type, inclusion body myositis, mild cognitive impairment (MCI) and Down's syndrome, in a subject.

Abstract: This invention provides compounds of Formula (I), having the structure where G1, G2, G3, G4, A1, A2, Y1, Y2, L1, Z, e and f are defined herein, or a pharmaceutically acceptable salt thereof, which are useful for treating or preventing cancer.

Abstract: A computer-implemented method of tracking transportation of material from a plurality of material origination sites to one or more material disposal sites can include receiving at a central database and at multiple different times, a plurality of electronic load tickets and corresponding electronic disposal confirmations and providing, for display at a user device, a graphical representation of material transported from the plurality of material origination sites to the one or more disposal sites, based on the received plurality of electronic load tickets and corresponding electronic disposal confirmations. In some implementations, each load ticket can identify material that has been transported from a site of material origination to a disposal site and a geographic location of the site of material origination, and each corresponding disposal confirmation can identify a quantity of material transported from the site of material origination to the disposal site and a type classification for the material.

Abstract: A method of performing debris clean-up following a disaster event can include creating an electronic load ticket for a pre-registered debris transporter to transport a load of debris from a site of debris origin to a site where the load of debris is to be emptied from the transporter; following transport of the load of debris to the second site, reading, from the electronic information storage device and to a portable computing device, the information uniquely identifying the debris transporter and the electronic load ticket; and upon verification that no alteration has been made to the transporter, receiving at the portable computing device information describing the load of debris that has been transported. In some implementations, the electronic load ticket includes information identifying the geographic location of debris origin, and is electronically stored on a portable electronic information storage device that contains information uniquely identifying the debris transporter.

Abstract: Compounds of Formula (I), are provided where T is CHO, COR8, or C(OH)R1R2; R1 and R2 are hydrogen, optionally substituted lower alkyl, CF3, optionally substituted alkenyl, or optionally substituted alkynyl; R3 is hydrogen or optionally substituted lower alkyl; R4 is (CF3)nalkyl, (CF3)n(substitutedalkyl), (CF3)nalkylphenyl, (CF3)nalkyl(substitutedphenyl), or (F)ncycloalkyl; n=1-3; R5 is hydrogen, halogen, CF3, diene fused to Y when Y?C, or substituted diene fused to Y when Y?C; W, Y and Z are C, CR6 or N where at least one of W, Y or Z are C; R6 is hydrogen, halogen, or optionally substituted lower alkyl; X is O, S, SO2, or NR7; R7 is hydrogen, optionally substituted lower alkyl, optionally substituted benzyl, or optionally substituted phenyl; and R8 is lower alkyl, CF3, or optionally substituted phenyl. Methods of preparing and using these compounds for inhibiting beta amyloid production and for treatment of Alzheimer's Disease and Down's syndrome are also described.

Abstract: A compound of Formula (I), or pharmaceutically acceptable salts and/or hydrates or prodrugs thereof, wherein Formula (I) has the structure: is provided, wherein R1-R7 are defined herein. These compounds are useful in medicaments for treating a disease selected from the group consisting of Alzheimer's Disease, amyloid angiopathy, cerebral amyloid angiopathy, systemic amyloidosis, hereditary cerebral hemorrhage with amyloidosis of the Dutch type, inclusion body myositis, mild cognitive impairment (MCI) and Down's syndrome, in a subject.

Abstract: This invention provides smooth muscle cell proliferation inhibitors of formula I having the structure wherein R1, R2, R3, R4, and R5 are each, independently, hydrogen, acyl of 2-7 carbon atoms, haloacyl of 2-7 carbon atoms, nitroacyl of 2-7 carbon atoms, cyanoacyl of 2-7 carbon atoms, trifluoromethylacyl of 3-8 carbon atoms, or benzoyl in which the phenyl moiety is substituted with R8; R6 and R7 are each, independently, —OH, —OR9, O-tert-butyldimethylsilyl, O-trialkylsilyl of 1-6 carbon atoms per alkyl moiety, O-triphenylsilyl, R8, R10, R11, and R12 are each, independently, hydrogen, —CN, —NO2, halogen, CF3, alkyl of 1-6 carbon atoms, acetyl, benzoyl, or alkoxy of 1-6 carbon atoms; R9 is acyl of 2-7 carbon atoms, haloacyl of 2-7 carbon atoms, nitroacyl of 2-7 carbon atoms, cyanoacyl of 2-7 carbon atoms, trifluoromethylacyl of 3-8 carbon atoms, or benzoyl in which the phenyl moiety is substituted with R8; Y is O, S, NH, NMe, or CH2; W is halogen, —CN, CF3, alkyl of 1-6 carbon atoms, haloalkyl of 1

Abstract: This invention provides PAI-1 inhibiting compounds of Formula I: wherein: R1, R2, R3, and R4 are each H, alkyl, alkanoyl, halo, OH, aryl optionally substituted with R8, perfluoroalkyl, alkoxy, amino, alkylamino, dialkylamino, perfluoroalkoxy; R5 is H, alkyl, perfluoroalkyl, aryl optionally substituted with R8, alkanoyl, aroyl optionally substituted with R8; R6 is H, alkyl, alkylaryl, benzyl optionally substituted with R8, alkanoyl, aroyl optionally substituted with R8; R7 is H, alkyl, alkylaryl, aryl optionally substituted with R8; n is 0-6; A is COOH, or an acid mimic such as tetraazole, SO3H, PO3H2, tetronic acid, etc.; R8 is H, alkyl, cycloalkyl, alkanoyl, halo, OH, perfluoroalkyl, alkoxy, amino, alkylamino, dialkylamino, perfluoroalkoxy; or a pharmaceutically acceptable salt thereof; as well as pharmaceutical compositions and methods of treatment using these compounds.

Abstract: This invention provides smooth muscle cell proliferation inhibitors of formula I having the structure wherein R1, R2, R3, R4, and R5 are each, independently, hydrogen, acyl of 2-7 carbon atoms, haloacyl of 2-7 carbon atoms, nitroacyl of 2-7 carbon atoms, cyanoacyl of 2-7 carbon atoms, trifluoromethylacyl of 3-8 carbon atoms, or benzoyl in which the phenyl moiety is substituted with R8; R6 and R7 are each, independently, —OH, —OR9, O-tert-butyldimethylsilyl, O-trialkylsilyl of 1-6 carbon atoms per alkyl moiety, O-triphenylsilyl, R8, R10, R11, and R12 are each, independently, hydrogen, —CN, —NO2, halogen, CF3, alkyl of 1-6 carbon atoms, acetyl, benzoyl, or alkoxy of 1-6 carbon atoms; R9 is acyl of 2-7 carbon atoms, haloacyl of 2-7 carbon atoms, nitroacyl of 2-7 carbon atoms, cyanoacyl of 2-7 carbon atoms, trifluoromethylacyl of 3-8 carbon atoms, or benzoyl in which the phenyl moiety is substituted with R8; Y is O, S, NH, NMe, or CH2; W is halogen, —CN, CF3, alkyl of 1-6 carbon atoms, haloalkyl of

Abstract: The present invention relates generally to substituted heteroaryl benzofuran acids and methods of using them.